Drug makers that agree to provide access to experimental treatments under the Right to Try act may be putting the future approval of their treatments at risk, some CEOs argue.
Biotech Executives Fret Over Hassles And Uncertainties Of ‘Right To Try’
Drug makers that agree to provide access to experimental treatments under the Right to Try act may be putting the future approval of their treatments at risk, some CEOs argue.